Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96HY6
UPID:
DDRGK_HUMAN
Alternative names:
Dashurin; UFM1-binding and PCI domain-containing protein 1
Alternative UPACC:
Q96HY6; A6NIU5; C9JSZ5; Q9BW47
Background:
DDRGK domain-containing protein 1, also known as Dashurin, plays a pivotal role in cellular processes, including reticulophagy, by acting as a substrate adapter for ufmylation. This protein is essential in responding to endoplasmic reticulum stress, facilitating the recruitment of the E3 UFM1-protein ligase UFL1, and promoting the ufmylation of proteins such as RPN1 and RPL26/uL24. Its involvement in regulating the unfolded protein response and essential processes like hematopoiesis and the inflammatory response underscores its biological significance.
Therapeutic significance:
DDRGK domain-containing protein 1's link to Spondyloepimetaphyseal dysplasia, Shohat type, a skeletal dysplasia affecting cartilage development, highlights its therapeutic potential. Understanding its role could lead to novel therapeutic strategies targeting skeletal dysplasias and other related disorders.